Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes

Jon G. Mabley, Alex Rabinovitch, Wilma Suarez-Pinzon, György Haskó, Pál Pacher, Robert Power, Gary Southan, Andrew Salzman, Csaba Szabo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Inosine, a naturally occurring purine, was long considered to be an inactive metabolite of adenosine. However, recently inosine has been shown to be an immunomodulator and anti-inflammatory agent. The aim of this study was to determine whether inosine influences anti-inflammatory effects and affects the development of type 1 diabetes in murine models. Type 1 diabetes was induced either chemically by streptozotocin or genetically using the nonobese diabetic mouse (NOD) model. Mice were treated with inosine (100 or 200 mg kg-1d-1) and diabetes incidence was monitored. The effect of inosine on pancreas immune cell infiltration, oxidative stress, and cytokine profile also was determined. For the transplantation model islets were placed under the renal capsule of NOD mice and inosine (200 mg kg-1d-1) treatment started the day of islet transplantation. Graft rejection was diagnosed by return of hyperglycemia accompanied by glucosuria and ketonuria. inosine reduced the incidence of diabetes in both streptozotocin-induced diabetes and spontaneous diabetes in NOD mice. Inosine decreased pancreatic leukocyte infiltration and oxidative stress in addition to switching the cytokine profile from a Th1 to a Th2 profile. Inosine prolonged pancreatic islet graft survival, increased the number of surviving β cells, and reduced the number of infiltrating leukocytes. Inosine protects against both the development of diabetes and against the rejection of transplanted islets. The purine exerts anti-inflammatory effects in the pancreas, which is its likely mode of action. The use of inosine should be considered as a potential preventative therapy in humans susceptible to developing Type 1 diabetes and as a possible antirejection therapy for islet transplant recipients.

Original languageEnglish (US)
Pages (from-to)96-104
Number of pages9
JournalMolecular Medicine
Volume9
Issue number3-4
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Inosine
Inbred NOD Mouse
Streptozocin
Type 1 Diabetes Mellitus
Islets of Langerhans Transplantation
Anti-Inflammatory Agents
Pancreas
Oxidative Stress
Leukocytes
Cytokines
Ketosis
Experimental Diabetes Mellitus
Incidence
Graft Rejection
Immunologic Factors
Graft Survival
Islets of Langerhans
Hyperglycemia
Adenosine
Immunosuppression

ASJC Scopus subject areas

  • Genetics

Cite this

Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. / Mabley, Jon G.; Rabinovitch, Alex; Suarez-Pinzon, Wilma; Haskó, György; Pacher, Pál; Power, Robert; Southan, Gary; Salzman, Andrew; Szabo, Csaba.

In: Molecular Medicine, Vol. 9, No. 3-4, 03.2003, p. 96-104.

Research output: Contribution to journalArticle

Mabley, JG, Rabinovitch, A, Suarez-Pinzon, W, Haskó, G, Pacher, P, Power, R, Southan, G, Salzman, A & Szabo, C 2003, 'Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes', Molecular Medicine, vol. 9, no. 3-4, pp. 96-104.
Mabley, Jon G. ; Rabinovitch, Alex ; Suarez-Pinzon, Wilma ; Haskó, György ; Pacher, Pál ; Power, Robert ; Southan, Gary ; Salzman, Andrew ; Szabo, Csaba. / Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. In: Molecular Medicine. 2003 ; Vol. 9, No. 3-4. pp. 96-104.
@article{0d791ec7d87841969dd947fb37b1b4cc,
title = "Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes",
abstract = "Inosine, a naturally occurring purine, was long considered to be an inactive metabolite of adenosine. However, recently inosine has been shown to be an immunomodulator and anti-inflammatory agent. The aim of this study was to determine whether inosine influences anti-inflammatory effects and affects the development of type 1 diabetes in murine models. Type 1 diabetes was induced either chemically by streptozotocin or genetically using the nonobese diabetic mouse (NOD) model. Mice were treated with inosine (100 or 200 mg kg-1d-1) and diabetes incidence was monitored. The effect of inosine on pancreas immune cell infiltration, oxidative stress, and cytokine profile also was determined. For the transplantation model islets were placed under the renal capsule of NOD mice and inosine (200 mg kg-1d-1) treatment started the day of islet transplantation. Graft rejection was diagnosed by return of hyperglycemia accompanied by glucosuria and ketonuria. inosine reduced the incidence of diabetes in both streptozotocin-induced diabetes and spontaneous diabetes in NOD mice. Inosine decreased pancreatic leukocyte infiltration and oxidative stress in addition to switching the cytokine profile from a Th1 to a Th2 profile. Inosine prolonged pancreatic islet graft survival, increased the number of surviving β cells, and reduced the number of infiltrating leukocytes. Inosine protects against both the development of diabetes and against the rejection of transplanted islets. The purine exerts anti-inflammatory effects in the pancreas, which is its likely mode of action. The use of inosine should be considered as a potential preventative therapy in humans susceptible to developing Type 1 diabetes and as a possible antirejection therapy for islet transplant recipients.",
author = "Mabley, {Jon G.} and Alex Rabinovitch and Wilma Suarez-Pinzon and Gy{\"o}rgy Hask{\'o} and P{\'a}l Pacher and Robert Power and Gary Southan and Andrew Salzman and Csaba Szabo",
year = "2003",
month = "3",
language = "English (US)",
volume = "9",
pages = "96--104",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "3-4",

}

TY - JOUR

T1 - Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes

AU - Mabley, Jon G.

AU - Rabinovitch, Alex

AU - Suarez-Pinzon, Wilma

AU - Haskó, György

AU - Pacher, Pál

AU - Power, Robert

AU - Southan, Gary

AU - Salzman, Andrew

AU - Szabo, Csaba

PY - 2003/3

Y1 - 2003/3

N2 - Inosine, a naturally occurring purine, was long considered to be an inactive metabolite of adenosine. However, recently inosine has been shown to be an immunomodulator and anti-inflammatory agent. The aim of this study was to determine whether inosine influences anti-inflammatory effects and affects the development of type 1 diabetes in murine models. Type 1 diabetes was induced either chemically by streptozotocin or genetically using the nonobese diabetic mouse (NOD) model. Mice were treated with inosine (100 or 200 mg kg-1d-1) and diabetes incidence was monitored. The effect of inosine on pancreas immune cell infiltration, oxidative stress, and cytokine profile also was determined. For the transplantation model islets were placed under the renal capsule of NOD mice and inosine (200 mg kg-1d-1) treatment started the day of islet transplantation. Graft rejection was diagnosed by return of hyperglycemia accompanied by glucosuria and ketonuria. inosine reduced the incidence of diabetes in both streptozotocin-induced diabetes and spontaneous diabetes in NOD mice. Inosine decreased pancreatic leukocyte infiltration and oxidative stress in addition to switching the cytokine profile from a Th1 to a Th2 profile. Inosine prolonged pancreatic islet graft survival, increased the number of surviving β cells, and reduced the number of infiltrating leukocytes. Inosine protects against both the development of diabetes and against the rejection of transplanted islets. The purine exerts anti-inflammatory effects in the pancreas, which is its likely mode of action. The use of inosine should be considered as a potential preventative therapy in humans susceptible to developing Type 1 diabetes and as a possible antirejection therapy for islet transplant recipients.

AB - Inosine, a naturally occurring purine, was long considered to be an inactive metabolite of adenosine. However, recently inosine has been shown to be an immunomodulator and anti-inflammatory agent. The aim of this study was to determine whether inosine influences anti-inflammatory effects and affects the development of type 1 diabetes in murine models. Type 1 diabetes was induced either chemically by streptozotocin or genetically using the nonobese diabetic mouse (NOD) model. Mice were treated with inosine (100 or 200 mg kg-1d-1) and diabetes incidence was monitored. The effect of inosine on pancreas immune cell infiltration, oxidative stress, and cytokine profile also was determined. For the transplantation model islets were placed under the renal capsule of NOD mice and inosine (200 mg kg-1d-1) treatment started the day of islet transplantation. Graft rejection was diagnosed by return of hyperglycemia accompanied by glucosuria and ketonuria. inosine reduced the incidence of diabetes in both streptozotocin-induced diabetes and spontaneous diabetes in NOD mice. Inosine decreased pancreatic leukocyte infiltration and oxidative stress in addition to switching the cytokine profile from a Th1 to a Th2 profile. Inosine prolonged pancreatic islet graft survival, increased the number of surviving β cells, and reduced the number of infiltrating leukocytes. Inosine protects against both the development of diabetes and against the rejection of transplanted islets. The purine exerts anti-inflammatory effects in the pancreas, which is its likely mode of action. The use of inosine should be considered as a potential preventative therapy in humans susceptible to developing Type 1 diabetes and as a possible antirejection therapy for islet transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=0037972010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037972010&partnerID=8YFLogxK

M3 - Article

C2 - 12865945

AN - SCOPUS:0037972010

VL - 9

SP - 96

EP - 104

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 3-4

ER -